Posts in Knowledge Base

Novel Food or Not? How to Check Your Ingredient

Novel Food or Not? Checking Supplement Ingredients Before Launch in the EU

How to determine whether an ingredient is a novel food in the EU, using the 15 May 1997 cut-off and the Novel Food Catalogue.

Food Supplement Labelling Requirements in the EU

Food Supplement Labelling in the EU: The Mandatory Particulars and the Statements You Cannot Make

Mandatory labelling particulars for food supplements under Directive 2002/46/EC and Regulation 1169/2011, explained step by step.

Health Claims on Food Supplements (Reg. 1924/2006)

Health Claims on Food Supplements: Regulation (EC) 1924/2006, the Authorised List and the On-Hold Botanical Problem

Which health claims are allowed on food supplements in the EU, how on-hold botanical claims work, and how to stay compliant.

Pet Supplements in the EU: Feed or Medicine?

Pet Supplements in the EU: Complementary Feed, Feed Additives and the Line with Veterinary Medicines

How EU law classifies pet supplements: complementary feed, feed additives or veterinary medicines, and what each route requires.

Food Supplement Registration in Greece & Cyprus

Food Supplement Registration in Greece and Cyprus: Notification, Licensing and Where the Two Systems Differ

How to notify or license a food supplement in Greece (EOF) and Cyprus: routes, timelines and documents. Regulatory guidance from PQRA.

ISO Certification for Life-Sciences Companies: 13485, 9001 and 27001

The three ISO standards that matter most in life sciences — and what the 2026 ISO 9001 revision means for companies certified today.

GxP Training Mandates: What EU GMP and GDP Actually Require

Training is a legal obligation under EU GMP and GDP. What the rules require and how to build a training system that survives inspection.

Biosimilar Market Access in the EU: Turning Approval into Uptake

Approval is only the start. How tenders, interchangeability policy and payer evidence decide whether a biosimilar actually gains share.

Biosimilars in 2026: EMA Moves Away from the Comparative Efficacy Study

The EMA no longer expects comparative efficacy studies for well-characterised biosimilars. What the tailored clinical approach means for developers.

Pharmacovigilance in 2026: What Regulation (EU) 2025/1466 Changes for Your Safety System

New EU pharmacovigilance rules apply from February 2026. Here is what changes for reporting, signal management and inspection readiness.